Efficacy of Anti-TNF Therapy for the Treatment of Patients with Moderate-to-Severe Inflammatory Bowel Disease; a First Iranian Report.
Anti-TNF drug
CinnoRA®
Inflammatory Bowel disease
Infliximab
Journal
Middle East journal of digestive diseases
ISSN: 2008-5230
Titre abrégé: Middle East J Dig Dis
Pays: Iran
ID NLM: 101535395
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
entrez:
22
2
2020
pubmed:
23
2
2020
medline:
23
2
2020
Statut:
ppublish
Résumé
BACKGROUND The anti-TNF drugs are shown to be highly effective in treatment of patients with moderate-tosevere inflammatory bowel disease (IBD). Here, we aimed to assess the efficacy and safety of antiTNF therapy at the national level. METHODS IBD patients aged 15 > years who received Infliximab and/or CinnoRA® between 2013 to July 2018 were identified. The data extracted from medical dossier and telephonic interview. The efficacy of therapy was defined as time to drug discontinuation or need for IBD-related surgery. The safety was assessed based on patient's reported adverse events. RESULTS We included 315 patients. The mean age of patients was 37.2 years and 62.2% of them developed the disease before age 30 years. Involvement of masculoskeletal system was reported in 7.3% of patients. Partial and complete response to Anti-TNF therapy was seen in 67% of patients. About 16% of patients did not respond to induction therapy and 16.9% of patients lost their response to Anti-TNF during one year. No serious adverse events, serious opportunistic infection, tuberculosis and malignancies reported by patients. Two patients reported pneumonia. CONCLUSION This study for the first time in our country, provides the evidences for efficacy of anti-TNF therapy in moderate to severe IBD patients.
Identifiants
pubmed: 32082516
doi: 10.15171/mejdd.2020.158
pmc: PMC7023648
doi:
Types de publication
Journal Article
Langues
eng
Pagination
12-18Informations de copyright
© 2020 The Author(s).
Déclaration de conflit d'intérêts
CONFLICT OF INTEREST The authors declare no conflict of interest related to this work.
Références
Int J Mol Sci. 2019 May 23;20(10):
pubmed: 31126015
Ann Rheum Dis. 2004 May;63(5):508-16
pubmed: 15082480
Gastroenterology. 2012 Feb;142(2):257-65.e1-3
pubmed: 22062358
Curr Opin Gastroenterol. 2014 Jul;30(4):378-84
pubmed: 24840000
Am J Gastroenterol. 2011 Feb;106(2):199-212; quiz 213
pubmed: 21045814
Popul Health Metr. 2009 Jun 15;7:9
pubmed: 19527516
Nat Rev Immunol. 2014 May;14(5):329-42
pubmed: 24751956
Scand J Gastroenterol. 2017 Oct;52(10):1086-1092
pubmed: 28622097
Aliment Pharmacol Ther. 2011 May;33(9):987-95
pubmed: 21366636
Inflamm Bowel Dis. 2015 Jan;21(1):182-97
pubmed: 25222660
Aliment Pharmacol Ther. 2015 Apr;41(7):613-23
pubmed: 25652884
Lancet. 2002 May 4;359(9317):1541-9
pubmed: 12047962
N Engl J Med. 2005 Dec 8;353(23):2462-76
pubmed: 16339095
Gastroenterology. 2012 Jan;142(1):46-54.e42; quiz e30
pubmed: 22001864
Acta Med Iran. 2012;50(6):363-72
pubmed: 22837114
Aliment Pharmacol Ther. 2018 Jan;47(2):212-218
pubmed: 29124774
Expert Opin Biol Ther. 2014 May;14(5):583-600
pubmed: 24502344
J Crohns Colitis. 2012 Mar;6(2):143-53
pubmed: 22325168
Aliment Pharmacol Ther. 2007 May 1;25(9):1055-60
pubmed: 17439506
Nat Rev Gastroenterol Hepatol. 2016 Jan;13(1):13-27
pubmed: 26627550
Arch Iran Med. 2016 Jan;19(1):2-15
pubmed: 26702742
Front Immunol. 2015 Sep 22;6:489
pubmed: 26441993
J Crohns Colitis. 2010 Oct;4(4):355-66
pubmed: 21122530
Am J Gastroenterol. 2011 Apr;106(4):685-98
pubmed: 21427713
Intest Res. 2014 Jul;12(3):214-20
pubmed: 25349595
N Engl J Med. 2004 Feb 26;350(9):876-85
pubmed: 14985485
Intest Res. 2014 Oct;12(4):281-6
pubmed: 25374493
Intest Res. 2017 Oct;15(4):487-494
pubmed: 29142516
Dig Liver Dis. 2013 Sep;45(9):738-43
pubmed: 23683530